Exact Mass: 968.5497

Exact Mass Matches: 968.5497

Found 17 metabolites which its exact mass value is equals to given mass value 968.5497, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

H-Val-pro-asn-leu-pro-gln-arg-phe-NH2

2-({1-[2-(2-{[1-(2-amino-3-methylbutanoyl)pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido)-4-methylpentanoyl]pyrrolidin-2-yl}formamido)-N-{1-[(1-carbamoyl-2-phenylethyl)carbamoyl]-4-[(diaminomethylidene)amino]butyl}pentanediamide

C45H72N14O10 (968.5556)


   

PE(DiMe(11,5)/LTE4)

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-{[(2R)-1-{[(2-aminoethoxy)(hydroxy)phosphoryl]oxy}-3-{[11-(3,4-dimethyl-5-pentylfuran-2-yl)undecanoyl]oxy}propan-2-yl]oxy}-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C50H85N2O12PS (968.5561)


PE(DiMe(11,5)/LTE4) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(DiMe(11,5)/LTE4), in particular, consists of one chain of one 12,15-epoxy-13,14-dimethyleicosa-12,14-dienoyl at the C-1 position and one chain of Leukotriene E4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   

PE(LTE4/DiMe(11,5))

(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-amino-3-[(2R)-3-{[(2-aminoethoxy)(hydroxy)phosphoryl]oxy}-2-{[11-(3,4-dimethyl-5-pentylfuran-2-yl)undecanoyl]oxy}propoxy]-3-oxopropyl]sulphanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C50H85N2O12PS (968.5561)


PE(LTE4/DiMe(11,5)) is an oxidized phosphatidylethanolamine (PE). Oxidized phosphatidylethanolamines are glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylethanolamines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylethanolamines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PE(LTE4/DiMe(11,5)), in particular, consists of one chain of one Leukotriene E4 at the C-1 position and one chain of 12,15-epoxy-13,14-dimethyleicosa-12,14-dienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PEs can be synthesized via three different routes. In one route, the oxidized PE is synthetized de novo following the same mechanisms as for PEs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PE backbone, mainly through the action of LOX (PMID: 33329396).

   
   

PIM1 32:2

2-O-(alpha-D-Manp)-(1-(9Z,12Z-octadecadienoyl)-2-tetradecanoyl-sn-glycero-3-phospho-1-myo-inositol)

C47H85O18P (968.5473)


   

Neuropeptide VF (124-131) (human) trifluoroacetate salt

Neuropeptide VF (124-131) (human) trifluoroacetate salt

C45H72N14O10 (968.5556)


   

H-Val-pro-asn-leu-pro-gln-arg-phe-NH2

2-({1-[2-(2-{[1-(2-amino-3-methylbutanoyl)pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido)-4-methylpentanoyl]pyrrolidin-2-yl}formamido)-N-{1-[(1-carbamoyl-2-phenylethyl)carbamoyl]-4-[(diaminomethylidene)amino]butyl}pentanediamide

C45H72N14O10 (968.5556)


   
   
   

Ac2PIM1 16:1_16:1

Ac2PIM1 16:1_16:1

C47H85O18P (968.5473)


   

Ac2PIM1 14:0_18:2

Ac2PIM1 14:0_18:2

C47H85O18P (968.5473)


   

Ac2PIM1 18:2_14:0

Ac2PIM1 18:2_14:0

C47H85O18P (968.5473)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-[[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropyl] (5E,8E,11E,14E,17E,20E)-tricosa-5,8,11,14,17,20-hexaenoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-[[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropyl] (5E,8E,11E,14E,17E,20E)-tricosa-5,8,11,14,17,20-hexaenoate

C54H80O15 (968.5497)


   

PIM1(16:0/16:2(9Z,12Z))

PIM1(16:0/16:2(9Z,12Z))

C47H85O18P (968.5473)


   

2-[6-ethyl-2-hydroxy-5-(2-methylbutyl)oxan-2-yl]-2-hydroxy-n-{6,9,23,29-tetrahydroxy-10,13-diisopropyl-6,24-dimethyl-2,8,11,15,22,25-hexaoxo-12-oxa-3,9,16,17,23,26,27-heptaazatetracyclo[24.4.0.0³,⁷.0¹⁶,²¹]triacontan-14-yl}propanimidic acid

2-[6-ethyl-2-hydroxy-5-(2-methylbutyl)oxan-2-yl]-2-hydroxy-n-{6,9,23,29-tetrahydroxy-10,13-diisopropyl-6,24-dimethyl-2,8,11,15,22,25-hexaoxo-12-oxa-3,9,16,17,23,26,27-heptaazatetracyclo[24.4.0.0³,⁷.0¹⁶,²¹]triacontan-14-yl}propanimidic acid

C45H76N8O15 (968.543)


   

(2r)-2-[(2r,5r,6r)-6-ethyl-2-hydroxy-5-[(2s)-2-methylbutyl]oxan-2-yl]-2-hydroxy-n-[(1r,6r,7s,10s,13s,14s,21r,24s,29r)-6,9,23,29-tetrahydroxy-10,13-diisopropyl-6,24-dimethyl-2,8,11,15,22,25-hexaoxo-12-oxa-3,9,16,17,23,26,27-heptaazatetracyclo[24.4.0.0³,⁷.0¹⁶,²¹]triacontan-14-yl]propanimidic acid

(2r)-2-[(2r,5r,6r)-6-ethyl-2-hydroxy-5-[(2s)-2-methylbutyl]oxan-2-yl]-2-hydroxy-n-[(1r,6r,7s,10s,13s,14s,21r,24s,29r)-6,9,23,29-tetrahydroxy-10,13-diisopropyl-6,24-dimethyl-2,8,11,15,22,25-hexaoxo-12-oxa-3,9,16,17,23,26,27-heptaazatetracyclo[24.4.0.0³,⁷.0¹⁶,²¹]triacontan-14-yl]propanimidic acid

C45H76N8O15 (968.543)


   

(2s)-2-[(2r,5r,6r)-6-ethyl-2-hydroxy-5-[(2s)-2-methylbutyl]oxan-2-yl]-2-hydroxy-n-[(1r,6r,7s,10s,13s,14s,21r,24s,29r)-6,9,23,29-tetrahydroxy-10,13-diisopropyl-6,24-dimethyl-2,8,11,15,22,25-hexaoxo-12-oxa-3,9,16,17,23,26,27-heptaazatetracyclo[24.4.0.0³,⁷.0¹⁶,²¹]triacontan-14-yl]propanimidic acid

(2s)-2-[(2r,5r,6r)-6-ethyl-2-hydroxy-5-[(2s)-2-methylbutyl]oxan-2-yl]-2-hydroxy-n-[(1r,6r,7s,10s,13s,14s,21r,24s,29r)-6,9,23,29-tetrahydroxy-10,13-diisopropyl-6,24-dimethyl-2,8,11,15,22,25-hexaoxo-12-oxa-3,9,16,17,23,26,27-heptaazatetracyclo[24.4.0.0³,⁷.0¹⁶,²¹]triacontan-14-yl]propanimidic acid

C45H76N8O15 (968.543)